This low sensitivity of PRAME suggests that when conventional histopathological evaluation and established ancillary diagnostic tests indicate a diagnosis of melanoma for a given challenging lesion, the absence of PRAME expression alone should not be considered sufficient grounds to reclassify the lesion as benign. This evidence concerns the gene PRAME and melanoma.